TrialCancer medicine2023

Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study.

Guo-Ming Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.